Associated Papers
Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
Meijer TG et al.
Cancers, 2024
38398132 (PubMed )
Supplement: cancers-16-00741-s001.zip › Table_S1-2_WES_results.xlsx › Table_S1
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Bakouny Z et al.
Nature Communications, 2021
33547292 (PubMed )
Supplement: 41467_2021_21068_MOESM4_ESM.xlsx › oncop_maf
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy.
Krug K et al.
Cell, 2020
Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.
Brough R et al.
Oncogene, 2018
29915391 (PubMed )
Supplement: 41388_2018_368_MOESM7_ESM.xlsx › Supplementary_Data_1
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL et al.
Plos One, 2018
29641532 (PubMed )
Supplement: pone.0194098.s003.xlsx › UK10K_AD
Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities.
Lapek JD et al.
Nature Biotechnology, 2017
28892078 (PubMed )
Supplement: NIHMS73743-supplement-Supplementary_tables.zip › Supplementary_Table_10_Proteins_with_Nonsense_Mutations_26_Breast_Cancer_Cell_Lines.xlsx › Sheet2
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Select a paper to view details